134 related articles for article (PubMed ID: 15564947)
1. Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans.
Skarke C; Langer M; Jarrar M; Schmidt H; Geisslinger G; Lötsch J
Anesthesiology; 2004 Dec; 101(6):1394-9. PubMed ID: 15564947
[TBL] [Abstract][Full Text] [Related]
2. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier.
Bourasset F; Cisternino S; Temsamani J; Scherrmann JM
J Neurochem; 2003 Sep; 86(6):1564-7. PubMed ID: 12950465
[TBL] [Abstract][Full Text] [Related]
3. Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-beta-D-glucuronide.
Bourasset F; Scherrmann JM
Life Sci; 2006 Apr; 78(20):2302-14. PubMed ID: 16309712
[TBL] [Abstract][Full Text] [Related]
4. The influence of inhibition of probenecid sensitive transporters on the central nervous system (CNS) uptake and the antinociceptive activity of morphine-6-glucuronide in rats.
Lötsch J; Schmidt R; Vetter G; Schmidt H; Skarke C; Niederberger E; Geisslinger G; Tegeder I
Neurosci Lett; 2002 Aug; 329(2):145-8. PubMed ID: 12165398
[TBL] [Abstract][Full Text] [Related]
5. The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers.
Lötsch J; Skarke C; Schmidt H; Grösch S; Geisslinger G
Anesthesiology; 2001 Dec; 95(6):1329-38. PubMed ID: 11748388
[TBL] [Abstract][Full Text] [Related]
6. Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein.
Lötsch J; Schmidt R; Vetter G; Schmidt H; Niederberger E; Geisslinger G; Tegeder I
J Neurochem; 2002 Oct; 83(2):241-8. PubMed ID: 12423235
[TBL] [Abstract][Full Text] [Related]
7. Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine.
Drewe J; Ball HA; Beglinger C; Peng B; Kemmler A; Schächinger H; Haefeli WE
Br J Clin Pharmacol; 2000 Sep; 50(3):237-46. PubMed ID: 10971308
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences.
Romberg R; Olofsen E; Sarton E; den Hartigh J; Taschner PE; Dahan A
Anesthesiology; 2004 Jan; 100(1):120-33. PubMed ID: 14695733
[TBL] [Abstract][Full Text] [Related]
9. Verapamil decreases glucuronidase activity in the gut.
Lötsch J; Sperker B; Kroemer HK; Geisslinger G
Biochem Pharmacol; 2002 Apr; 63(8):1575-8. PubMed ID: 11996900
[TBL] [Abstract][Full Text] [Related]
10. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide.
Penson RT; Joel SP; Roberts M; Gloyne A; Beckwith S; Slevin ML
Br J Clin Pharmacol; 2002 Apr; 53(4):347-54. PubMed ID: 11966664
[TBL] [Abstract][Full Text] [Related]
11. The influence of active transport systems on morphine -6-glucuronide transport in MDCKII and MDCK-PGP cells.
Sattari M; Routledge P; Mashayekhi S
Daru; 2011; 19(6):412-6. PubMed ID: 23008686
[TBL] [Abstract][Full Text] [Related]
12. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2003 Dec; 74(6):543-54. PubMed ID: 14663457
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers.
Lötsch J; Weiss M; Ahne G; Kobal G; Geisslinger G
Anesthesiology; 1999 Apr; 90(4):1026-38. PubMed ID: 10201674
[TBL] [Abstract][Full Text] [Related]
14. Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid.
Rengelshausen J; Göggelmann C; Burhenne J; Riedel KD; Mikus G; Walter-Sack I; Haefeli WE
Int J Clin Pharmacol Ther; 2007 Aug; 45(8):431-7. PubMed ID: 17725176
[TBL] [Abstract][Full Text] [Related]
15. Disposition of morphine-6-glucuronide and morphine in healthy volunteers.
Hanna MH; Peat SJ; Knibb AA; Fung C
Br J Anaesth; 1991 Jan; 66(1):103-7. PubMed ID: 1997044
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.
Meineke I; Freudenthaler S; Hofmann U; Schaeffeler E; Mikus G; Schwab M; Prange HW; Gleiter CH; Brockmöller J
Br J Clin Pharmacol; 2002 Dec; 54(6):592-603. PubMed ID: 12492606
[TBL] [Abstract][Full Text] [Related]
17. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers.
Murthy BR; Pollack GM; Brouwer KL
J Clin Pharmacol; 2002 May; 42(5):569-76. PubMed ID: 12017351
[TBL] [Abstract][Full Text] [Related]
18. Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate test.
Lötsch J; Tegeder I; Angst MS; Geisslinger G
Life Sci; 2000 May; 66(24):2393-403. PubMed ID: 10864101
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine.
Stuart-Harris R; Joel SP; McDonald P; Currow D; Slevin ML
Br J Clin Pharmacol; 2000 Mar; 49(3):207-14. PubMed ID: 10718775
[TBL] [Abstract][Full Text] [Related]
20. Influence of probenecid on the delivery of morphine-6-glucuronide to the brain.
Tunblad K; Hammarlund-Udenaes M; Jonsson EN
Eur J Pharm Sci; 2005 Jan; 24(1):49-57. PubMed ID: 15626577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
